Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
QNCX
QNCX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
QNCX News
Quince Therapeutics Shares Surge After Hours Despite Major Losses
Feb 13 2026
Benzinga
Quince Therapeutics Stock Plummets 52% Amid Financial Struggles
Feb 12 2026
Benzinga
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
Feb 12 2026
Benzinga
Quince Therapeutics Shares Surge on Strategic Review Announcement
Feb 11 2026
Benzinga
Teradata Quarterly Earnings Beat Expectations
Feb 11 2026
Benzinga
Major U.S. Indices Close Mixed with Notable Stock Movements
Feb 11 2026
Benzinga
Quince Therapeutics Shares Surge 300% Following Strategic Advisor Engagement
Feb 10 2026
Benzinga
U.S. Stocks Mixed in Morning Trading
Feb 10 2026
Benzinga
Quince Therapeutics Faces Strategic Review Amid 91.5% Stock Plunge
Feb 10 2026
stocktwits
Quince Therapeutics Stock Rises 54.15% Amid Strategic Advisory Engagement
Feb 10 2026
Benzinga
Credo Technology Raises Revenue Guidance Significantly
Feb 10 2026
Benzinga
Wall Street Analysts Adjust Ratings
Jan 30 2026
Benzinga
Quince Therapeutics Shares Plunge 90% After Disappointing Phase 3 Trial Results
Jan 30 2026
Benzinga
Quince's Clinical Trial Fails to Meet Key Endpoints
Jan 29 2026
stocktwits
Quince Therapeutics Reports Phase 3 Trial Results for A-T Treatment
Jan 29 2026
Businesswire
Quince Therapeutics' Clinical Trial Fails to Meet Primary Endpoint
Jan 29 2026
Newsfilter
Show More News
